Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial

IMPORTANCE: Many cancer subtypes, including KIT-mutant gastrointestinal stromal tumors (GISTs), are driven by activating mutations in tyrosine kinases and may initially respond to kinase inhibitors but frequently relapse owing to outgrowth of heterogeneous subclones with resistance mutations. KIT in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Wagner, Andrew J., Severson, Paul L., Shields, Anthony F., Patnaik, Amita, Chugh, Rashmi, Tinoco, Gabriel, Wu, Guoxian, Nespi, Marika, Lin, Jack, Zhang, Ying, Ewing, Todd, Habets, Gaston, Burton, Elizabeth A., Matusow, Bernice, Tsai, James, Tsang, Garson, Shellooe, Rafe, Carias, Heidi, Chan, Katrina, Rezaei, Hamid, Sanftner, Laura, Marimuthu, Adhirai, Spevak, Wayne, Ibrahim, Prabha N., Inokuchi, Kerry, Alcantar, Oscar, Michelson, Glenn, Tsiatis, Athanasios C., Zhang, Chao, Bollag, Gideon, Trent, Jonathan C., Tap, William D.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2021
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8267845/
https://ncbi.nlm.nih.gov/pubmed/34236401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2021.2086
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados